Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.

Authors :: Aredo, Jacqueline V.
Urisman, Anatoly
Gubens, Matthew A.
Mulvey, Claire
Allen, Greg M.
Rotow, Julia K.
Kerr, Daniel Lucas
Chakrabarti, Turja
Bacaltos, Bianca
Gee, Megan
Jones, Kirk
Aisner, Dara L.
Patil, Tejas
Schenk, Erin Lynn
Bivona, Trever G.
Riess, Jonathan W.
Coleman, Melissa
Kratz, Johannes Ruediger
Jablons, David
Blakely, Collin M.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8508-8508, 1p
Publication Year :: 2023

Full Text Access

Tools